GRA VentureLab company awarded $3 million from NIH to advance ischemia research
NeurOp, a biopharmaceutical GRA VentureLab company focused on treatments for central nervous systems disorders, has garnered $3 million from the NIH to further its ischemia research program. Specifically, NeurOp will focus the funding on bringing its lead molecule forward to an Investigational New Drug filing for the treatment of subarachnoid hemorrhage and those patients at risk for stroke.
According to Barney Koszalka, Ph.D., NeurOp president and CEO, “This grant, coupled with support from the Georgia Research Alliance, will accelerate our work to identify within the year a drug candidate for ischemia to advance into pre-IND studies.”
Based on technology developed in the laboratories of Ray Dingledine, Ph.D., at Emory University, NeurOp is developing treatments for depression, neuropathic pain, schizophrenia and Parkinson’s disease, in addition to ischemia. Read more here>